First epidemiological study: Omicron with significant immune escape
- Fasting for 16 hours a day may increase the risk of cardiovascular death by 91%
- FDA Approves Groundbreaking Gene Therapy from UK’s Orchard Therapeutics
- Breakthrough in CAR-T therapy: Tumors almost completely disappear in just 5 days
- Adapalene can effectively activate senescence in prostate cancer cells and increase NK cell anti-tumor activity
- mRNA Therapy Unveils Hidden Cancer Cells: BioNTech’s IL-2 Breakthrough
- “Blood Test for Cancer”: Accuracy Up to 83% for Colorectal Cancer
First epidemiological study: Omicron with significant immune escape
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- Japan: Over 10,000 Applications for Health Damage from COVID-19 Vaccines
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- ‘Elixir of Immortality’ Nicotinamide Riboside (NR) Virtually No Effect
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
First epidemiological study: Omicron with significant immune escape.
[Heavyweight] The first epidemiological study of Omicron causing superinfection, showing that the phenomenon of immune escape is more significant.
On December 2, 2021, Pulliam of Stellenbosch University in South Africa and others uploaded the first research paper on Omicron mutant strains on bioRxiv, the title is “Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa” (The increased risk of SARS-CoV-2 superinfection in South Africa is related to the Omicron mutant ).
This blockbuster study describes the epidemiology of Omicron’s repeated infections .
In a cohort of 2,796,982 patients previously infected with SARS-CoV-2, the study found 35,670 repeat infections before November 27.
Studies have found that, compared with wild-type strains, Beta and Delta mutant strains increase the risk of initial infection (first infection) in the population , but do not increase the risk of reinfection, that is to say, the immunity formed after initial infection is against reinfection. Still valid. Omicron is contrary to the prevalence of the above two mutant strains.
The study found that Omicron did not increase the risk of initial infection in the population, and even the risk of initial infection in the population was reduced; but it increased the risk of reinfection .
In the second and third peaks dominated by Beta and Delta mutant strains, the hazard ratios of repeated infections were 0.75 and 0.71, respectively. In South Africa’s recent fourth peak led by Omicron, the hazard ratio of repeated infections rose to 2.39 .
In other words, the immune escape phenomenon of Omicron may be more significant .
Therefore, it is critical to continue to monitor its epidemic and conduct serological research.
references:
https://www.medrxiv.org/content/10.1101/2021.11.11.21266068v2.full.pdf
First epidemiological study: Omicron with significant immune escape
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.